Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASCO 2017—making adifference in cancer care with you

ASCO 2017—making adifference in cancer care with you editorial memo (2017) 10:187–189 https://doi.org/10.1007/s12254-017-0364-y Gabriel Rinnerthaler Received: 31 October 2017 / Accepted: 31 October 2017 / Published online: 15 November 2017 © Springer-Verlag GmbH Austria, part of Springer Nature 2017 For the 2017 annual meeting of the American Society adjuvant setting, this trial confirms that positive re- of Clinical Oncology (ASCO) 5817 abstracts had been sults in the neoadjuvant setting might also be cau- submitted and 2463 were finally selected for presen- tiously transferred to the adjuvant setting. This further tation. To spread this enormous gain of knowledge, supports drug development within neoadjvant trials new ways of information exchange become increas- where clinical endpoints can be reached faster and ingly important. With webcasts and news tickers, pre- with substantially fewer participants compared to the sentations at international congresses can be followed adjuvant setting. The results from the OlympiAD trial, at home. Furthermore, continuing medical educa- investigating the poly ADP ribose polymerase (PARP) tion events and published reviews illuminate the pre- inhibitor olaparib in patients with metastatic breast sented data from different perspectives. In this spe- cancer harboring breast cancer gene (BRCA) germline cial edition, Austrian specialists summarize the im- mutations, demonstrated a superiority of olaparib portant and most http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASCO 2017—making adifference in cancer care with you

Loading next page...
 
/lp/springer-journals/asco-2017-making-adifference-in-cancer-care-with-you-2kzY1dulMX
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0364-y
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2017) 10:187–189 https://doi.org/10.1007/s12254-017-0364-y Gabriel Rinnerthaler Received: 31 October 2017 / Accepted: 31 October 2017 / Published online: 15 November 2017 © Springer-Verlag GmbH Austria, part of Springer Nature 2017 For the 2017 annual meeting of the American Society adjuvant setting, this trial confirms that positive re- of Clinical Oncology (ASCO) 5817 abstracts had been sults in the neoadjuvant setting might also be cau- submitted and 2463 were finally selected for presen- tiously transferred to the adjuvant setting. This further tation. To spread this enormous gain of knowledge, supports drug development within neoadjvant trials new ways of information exchange become increas- where clinical endpoints can be reached faster and ingly important. With webcasts and news tickers, pre- with substantially fewer participants compared to the sentations at international congresses can be followed adjuvant setting. The results from the OlympiAD trial, at home. Furthermore, continuing medical educa- investigating the poly ADP ribose polymerase (PARP) tion events and published reviews illuminate the pre- inhibitor olaparib in patients with metastatic breast sented data from different perspectives. In this spe- cancer harboring breast cancer gene (BRCA) germline cial edition, Austrian specialists summarize the im- mutations, demonstrated a superiority of olaparib portant and most

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Nov 15, 2017

References